Oral Disintegrating Tablets Make Dosing Challenges for Children Disappear CAPSULE: The oral disintegrating tablet meets the double challenge faced with young patients: dosing accuracy and ease of administration. This technology has the potential to revolutionize the pediatric drug market. By circumventing the need to swallow, these drugs make it easier for parents and caregivers to administer medications to children while increasing the potential for compliance.
Take steps to limit undesirable effects CAPSULE: With interest burgeoning in the use of disposables for the production of modern biopharmaceutical products, the scrutiny of leachables and extractables has moved into a higher gear. The recent trend toward new disposable methods of production means the risk of elastomer eluting from the components or breakdown product washing off the material is much greater. With the potential for leachables and extractables to have a marked effect on the quality and safety of protein therapeutics, the challenge is to find better testing methods to provide adequate sensitivity and specificity.
Containers critical to drug product safety and efficacy
CAPSULE: The landscape of pharmaceutical packaging is broad and diverse. At its center are the drug product manufacturers, whose business it is to produce innovative, safe, and effective medicines to treat disease. Critical to this business are drug product packaging systems, and critical to these packaging systems are the supply chains with all their various levels of individual suppliers. Effective partnerships between drug product manufacturers and packaging component/material suppliers are required to maintain the quality and integrity of the supply chain, particularly when it comes to high-risk dosage forms.
FROM OUR NEWSLETTER
Stay in the loop with our free, semi-monthly eNewsletter. Sign up today!
A recently published description of the outermost layer of the skin, the stratum corneum, may lead to better design of drugs for transdermal applications, researchers in Sweden suggested.
Branched molecules called dendrimers carried an anti-inflammatory drug across the blood-brain barrier in an animal model of cerebral palsy and showed positive effects, according to researchers in Baltimore.
A multi-component nanochain delivered doxorubin throughout tumors in two animal models of breast cancer, causing a robust anti-cancer effect, researchers in Cleveland reported.
